GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 5, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

DRUG

Tislelizumab combined with GEMOX (GOT) regimen

Tislelizumab 200mg on day 1；Gemcitabine 1000mg/m2 on day 1、8；Oxaliplatin 135mg/m2 on day 1；cycle 3 weeks

Trial Locations (2)

RECRUITING

Jia Wu, Hanzhou

NOT_YET_RECRUITING

1# Banshan East Rd. Zhejiang cancer hospital, Hangzhou

All Listed Sponsors

lead

Zhejiang Cancer Hospital

OTHER